Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice

Microbes and Infection

Volumn 9, Issue 7, 2007, Pages 821-828

  Scavone, Paola ^a   Miyoshi, Anderson ^b   Rial, Analía ^c   Chabalgoity, Alejandro ^c   Langella, Philippe ^d   Azevedo, Vasco ^b   Zunino, Pablo ^a  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Universidad de la Republica Instituto de Higiene   (Uruguay)

^d CEMAGREF   (France)

Author keywords

Fimbrial protein; Lactococcus lactis; MrpA; Mucosal immunisation; Proteus mirabilis; Urinary tract infection

Indexed keywords

BACTERIAL ANTIGEN; FIMBRIA PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVE VACCINE; PROTEIN MRPA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; FEMALE; KIDNEY; LACTOCOCCUS LACTIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEUS MIRABILIS; URINARY TRACT INFECTION; VACCINE PRODUCTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; INTERFERON TYPE II; LACTOCOCCUS LACTIS; MICE; PROTEUS INFECTIONS; PROTEUS MIRABILIS; SPLEEN; STATISTICS, NONPARAMETRIC; URINARY TRACT INFECTIONS; VACCINES, SYNTHETIC;

ANIMALIA; BACTERIA (MICROORGANISMS); LACTOCOCCUS LACTIS; MUS; PROTEUS MIRABILIS;

EID: 34250166130     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2007.02.023     Document Type: Article

References (28)

1. Stamm W.E., Martin S.M., and Bennett J.V. Epidemiology of nosocomial infections due to Gram negative bacilli: aspects relevant to development and use of vaccines. J. Infect. Dis. 136 (1977) S151-S160
2. Rozalski A., Sidorcyk Z., and Kotelko K. Potential virulence factors of Proteus bacilli. Microbiol. Mol. Biol. Rev. 61 (1997) 65-89
3. Coker C., Poore C.A., Li X., and Mobley H.L. Pathogenesis of Proteus mirabilis urinary tract infection. Microbes Infect. 2 (2000) 1497-1509
4. Li X., Lockatell C.V., Johnson D.E., and Mobley H.L. Identification of MrpI as the sole recombinase that regulates the phase variation of MR/P fimbria, a bladder colonization factor of uropathogenic Proteus mirabilis. Mol. Microbiol. 45 (2002) 865-874
5. Pellegrino R., Galvalisi U., Scavone P., Sosa V., and Zunino P. Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections. FEMS Immunol. Med. Microbiol. 36 (2003) 103-110
6. Li X., Erbe J.L., Lockatell C.V., Johnson D.E., Jobling M.G., Holmes R.K., and Mobley H.L. Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infect. Immun. 72 (2004) 7306-7310
7. Scavone P., Sosa V., Pellegrino R., Galvalisi U., and Zunino P. Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins. Microbes Infect. 6 (2004) 853-860
8. Wells J.M., Robinson K., Chamberlain L.M., Schofield K.M., and Le Page R.W. Lactic acid bacteria as vaccine delivery vehicles. Antonie Van Leeuwenhoek 70 (1996) 317-330
9. Pouwels P.H., Leer R.J., Shaw M., Heijne den Bak-Glashouwer M.J., Tielen F.D., Smit E., Martinez B., Jore J., and Conway P.L. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int. J. Food Microbiol. 26 (1998) 155-167
10. Xin K.Q., Hoshino Y., Toda Y., Igimi S., Kojima Y., Jounai N., Ohba K., Kushiro A., Kiwaki M., Hamajima K., Klinman D., and Okuda K. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 102 (2003) 223-228
11. Pontes D.S., Dorella F.A., Ribeiro L.A., Miyoshi A., Le Loir Y., Gruss A., Oliveira S.C., Langella P., and Azevedo V. Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen. J. Drug Target 11 (2003) 489-493
12. Bermudez-Humaran L.G., Cortes-Perez N.G., Lefevre F., Guimaraes V., Rabot S., Alcocer-Gonzalez J.M., Gratadoux J.J., Rodriguez-Padilla C., Tamez-Guerra R.S., Corthier G., Gruss A., and Langella P. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against Human Papillomavirus Type 16-induced tumors. J. Immunol. 175 (2005) 7297-7302
13. Sambrook J., Fritch E.F., and Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd Edition (1989), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
14. Birnboim H., and Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7 (1979) 1513-1523
15. Langella P., Le Loir Y., Ehrlich S.D., and Gruss A. Efficient plasmid mobilization by pIP501 in Lactococcus lactis subsp. Lactis. J. Bacteriol. 175 (1993) 5806-5813
16. Sanger F., Nicklen S., and Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 5463-5467
17. Bermudez-Humaran L.G., Langella P., Commissaire J., Gilbert S., Le Loir Y., L'Haridon R., and Corthier G. Controlled intra- or extracellular production of staphylococcal nuclease and ovine omega interferon in Lactococcus lactis. FEMS Microbiol. Lett. 29 (2003) 307-313
18. de Ruyter P.G., Kuipers O.P., and de Vos W.M. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl. Environ. Microbiol. 62 (1996) 3662-3667
19. van Asseldonk M., Rutten G., Oteman M., Siezen R.J., de Vos W.M., and Simons G. Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene 30 (1990) 155-160
20. Le Loir Y., Gruss A., Ehrlich S.D., and Langella P. A nine-residue synthetic propeptide enhances secretion efficiency of heterologous proteins in Lactococcus lactis. J. Bacteriol. 180 (1998) 1895-1903
21. Piard J.C., Hautefort I., Fischetti V.A., Ehrlich S.D., Fons M., and Gruss A. Cell wall anchoring of the Streptococcus pyogenes M6 protein in various lactic acid bacteria. J. Bacteriol. 179 (1997) 3068-3072
22. Zunino P., Geymonat L., Allen A.G., Preston A., Sosa V., and Maskell D.J. New aspects of the role of MR/P fimbriae in Proteus mirabilis urinary tract infection. FEMS Immunol. Med. Microbiol. 31 (2001) 113-120
23. Zunino P., Piccini C., and Legnani-Fajardo C. Flagellate and non-flagellate Proteus mirabilis in the development of experimental urinary tract infection. Microb. Pathog. 16 (1994) 379-385
24. Norton P.M., Brown H.W., Wells J.M., Macpherson A.M., Wilson P.W., and Le Page R.W. Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis. FEMS Immunol. Med. Microbiol. 14 (1996) 167-177
25. Bermudez-Humaran L.G., Cortes-Perez N.G., Le Loir Y., Alcocer-Gonzalez J.M., Tamez-Guerra R.S., de Oca-Luna R.M., and Langella P. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J. Med. Microbiol. 53 (2004) 427-433
26. Robinson K., Chamberlain L.M., Lopez M.C., Rush C.M., Marcotte H., Le Page R.W., and Wells J.M. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect. Immun. 72 (2004) 2753-2761
27. Studier F.W., and Moffatt B.A. Use of a bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. Mol. Biol. 189 (1986) 113-130
28. Kuipers O.P., de Ruyter P.G.G.A., Kleerebezem M., and de Vos W.M. Quorum sensing controlled gene expression in lactic acid bacteria. Biotechnol 64 (1998) 15-21